Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs
Walter H. Moos, Douglas V. Faller, Ioannis P. Glavas, David N. Harpp, Iphigenia Kanara, Anastasios Mavrakis, Julie Pernokas, Mark Pernokas, Carl A. Pinkert, Whitney R. Powers, Konstantina Sampani, Kosta Steliou, Demetrios G. Vavvas, Robert Zamboni, Krishna Kodukula, Xiaohong Chen
Abstract
a little over two decades ago, it has become ever more apparent that when Klotho pathways go awry, oxidative stress and mitochondrial dysfunction take over, and age-related chronic disorders are likely to follow. The physiological consequences can be wide ranging, potentially wreaking havoc on the brain, eye, kidney, muscle, and more. Central nervous system disorders, neurodegenerative in nature, and especially those affecting the myelin sheath, represent worthy targets for advancing therapies that act upon Klotho pathways. Current drugs for these diseases, even therapeutics that are disease modifying rather than treating only the symptoms, leave much room for improvement. It is thus no wonder that this topic has caught the attention of biomedical researchers around the world.